Nanjing Leads Biolabs Co Ltd (09887.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−217.5x

Market Cap

HKD 12.73B

MomentumView details →

1D Return

−5.47%

YTD Return

+25.49%

RSI (14)

44.7

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−217.5x

Market Cap

HKD 12.73B

RSI (14)

44.7

MomentumView details →

1D Return

−5.47%

YTD Return

+25.49%

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−38.19%

EBITDA Margin

−22.34%

ROE (TTM)

−5.30%

ROA (TTM)

−3.77%

Asset Turnover

0.10x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+349.62%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 1.30

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.22x

Current Ratio

3.37x

Quick Ratio

3.25x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

195.48M

Net Income (TTM)

−74.66M

Op. CF (TTM)

−26.36M

Next earningsMar 29, 2027 →

Latest newsMore news →

Virelizhibo announced that its self-developed drug Weilixin (opartuzumab, PDL1/4-1BB bispecific antibody, LBL-024) has completed the safety run-in phase and entered the expansion stage of a Phase II clinical study for first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).11d ago

Similar companies

Madrigal Pharmaceuticals, Inc.MDGL BioMarin Pharmaceutical Inc.BMRN Halozyme Therapeutics, Inc.HALO Ascentage Pharma Group International06855.HK Jiangsu Zenergy Battery Technologies Group Co., Ltd.03677.HK 迈威生物-U688062.SH Find similar companies →

Latest newsMore news →

Virelizhibo announced that its self-developed drug Weilixin (opartuzumab, PDL1/4-1BB bispecific antibody, LBL-024) has completed the safety run-in phase and entered the expansion stage of a Phase II clinical study for first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).11d ago